Physiological Research Pre-Press Article

Proteasomes in lungs from organ donors and patients with end-stage pulmonary diseases

Short title: Proteasomes in normal and diseased lungs

Todd A. Baker¹, Harold H. Bach IV^{1/2}, Richard L. Gamelli¹, Robert B. Love^{3/4}, Matthias Majetschak^{1/2}

¹Burn and Shock Trauma Research Institute - Department of Surgery, ²Department of Molecular Pharmacology and Therapeutics, ³Department of Thoracic and Cardiovascular Surgery, Loyola University Chicago, Maywood, IL, USA.

⁴: Current address: Department of Surgery, Medical College of Wisconsin, Milwaukee.

Parts of this research have been presented at the Clinical Congress of the American College of Surgeons 2011 (J Am Coll Surg, 2011, 213: 4-5)

Corresponding Author: Matthias Majetschak Loyola University Chicago 2160 S. 1st Avenue, Maywood, IL 60153 Phone: (708) 327-2472, Fax: (708) 327- 2813 Email: mmajetschak@lumc.edu

<u>Summary</u>

Proteasomes appear to be involved in the pathophysiology of various acute and chronic lung diseases. Information on the human lung proteasome in health and disease, however, is sparse. Therefore, we studied whether end-stage pulmonary diseases are associated with alterations in lung 20S/26S proteasome content, activity and 20S subunit composition. Biopsies were obtained from donor lungs (n=7) and explanted lungs from patients undergoing lung transplantation because of end stage chronic obstructive pulmonary disease (COPD; n=7), idiopathic pulmonary fibrosis (IPF, n=7) and pulmonary sarcoidosis (n=5). 20S/26S proteasomes in lung extracts were quantified by ELISA, chymotrypsin-like proteasome peptidase activities measured and 20S proteasome β subunits analyzed by Western blot. As compared with donor lungs, proteasome content was increased in IPF and sarcoidosis, but not in COPD. The relative distribution of free 20S and 26S proteasomes was similar; 20S proteasome was predominant in all extracts. Proteasome peptidase activities in donor and diseased lungs were indistinguishable. All extracts contained a mixed composition of inducible 20S β immuno-subunits and their constitutive counterparts; a disease associated distribution could not be identified. A higher content of lung proteasomes in IPF and pulmonary sarcoidosis may contribute to the pathophysiology of human fibrotic lung diseases.

Key words: 20S proteasome, 26S proteasome, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, pulmonary sarcoidosis

Introduction:

Proteasomes are important proteolytic machineries in all eukaryotic cells and among the major proteolytic systems that contribute to protein guality control (Orlowski 1990; Baumeister et al. 1998; Hershko and Ciechanover 1998; Groll and Huber 2004). Proteasomes consist of a cylinder-shaped protein complex (20S core particle, 20S) which can be capped at each end by a 19S regulator complex when ATP/Mg²⁺ is present and is then termed 26S proteasome (26S). The 20S core particle is composed of four stacked rings. Each ring consists of seven α - and β -type subunits ($\alpha_{1-7}\beta_{1-7}\beta_{1-7}\alpha_{1-7}$ 7). In eukaryotic 20S core particles, the proteolytic active sites are located in the subunits β 1, β 2 and β 5 of the inner rings. These subunits can be replaced by inducible subunits B1i, B2i and B5i. As two of these subunits are encoded within the MHC class II region, they are referred to as immuno-(i)-subunits (Rock and Goldberg 1999; Groll and Huber 2004; Gomes et al. 2006; Gallastegui and Groll 2010; Guillaume et al. 2010; Sijts and Kloetzel 2011). Whereas proteins that have been covalently modified with ubiquitin are substrates for ATP/Mg²⁺ dependent degradation by the 26S proteasome, the 20S core particle alone contributes to the removal of misfolded and damaged proteins, independent of ATP/Mg²⁺ or ubiquitylation (Eytan et al. 1993; Orlowski and Wilk 2003).

Several lines of evidence suggest that proteasomes are involved in the pathophysiology of various acute and chronic lung diseases. Besides their involvement in the pathophysiology of lung cancer and pulmonary inflammation, proteasomal dysfunction is thought to contribute to proteostasis imbalance in chronic obstructive lung disease (COPD) and idiopathic pulmonary fibrosis (IPF) (Bunn 2004; Malhotra *et al.* 2009; Weiss *et al.* 2010; Bodas *et al.* 2012; Zhao *et al.* 2012).

Curative treatment strategies for COPD, IPF or pulmonary sarcoidosis are currently not available and lung transplantation is the only treatment option for many patients with advanced disease. Thus, a better understanding of the regulation of the proteasome in normal and diseased lungs is essential to assess its role in pulmonary pathophysiology and as a possible drug target. Information on the human lung proteasome in health and disease, however, is sparse. Therefore, it was the aim of this pilot study to determine whether end-stage pulmonary diseases are associated with alterations in lung 20S/26S proteasome content, activity and 20S subunit composition.

Materials and Methods:

Lung biopsies: This study was approved by the Institutional Review Board and informed consent was obtained for the use of the lung biopsies. Lung biopsies were obtained from discarded donor lungs that fulfilled transplantation criteria (n = 7, age: 56 \pm 27 years, 3/1/3 male/female/unknown) and from explanted lungs from patients undergoing single or double lung transplantation because of end stage COPD (n = 7, age: 64 \pm 6 years, 6/1 male/female), IPF (n=7, age: 67 \pm 5 years, 5/2 male/female) or sarcoidosis (n = 5, 1/4 male/female, age: 51 \pm 4 years). Sixteen of the transplanted patients were of Caucasian origin, one patient with sarcoidosis was of African-American origin and one patient with IPF was of Hispanic origin. The diagnosis was confirmed by histology in all transplanted patients. Biopsies were snap frozen in liquid nitrogen immediately after resection and stored at - 70°C until further processing.

<u>Tissue processing</u>: Snap frozen tissues were homogenized in 1/10 phosphate

buffered saline, 2 mM ATP, 5 mM MgCl₂, pH 7.4 (1:5 weight/volume), centrifuged (16,600g, 4°C, 30 min) and supernatants (= extracts) aliquoted, as described (Majetschak *et al.* 2008a; Geng *et al.* 2009). All measurements in tissue extracts were standardized to total protein content (Lowry *et al.* 1951) and are reported per mg of protein.

Proteasome enzyme linked immunosorbent assays (ELISA): The concentration of total 20S proteasomes (free 20S core particles and 20S core particles within the 26S proteasome complex) and 26S proteasomes in lung extracts was quantified as described in detail previously (Majetschak and Sorell 2008). For the calculation of the molar concentration of 20S core particles, a molecular mass of 700 kDa was used. For the 26S proteasome complex, a molecular mass of 1.7 MDa was assumed to account for a mixture of 20S core complexes that are capped with either one or two 19S regulator complexes. The concentration of free 20S proteasomes was calculated as concentration of total 20S proteasomes minus the concentration of 26S proteasome complexes.

Proteasome peptidase activity assay. Proteasome peptidase activities (=total peptidase activity minus activity in the presence of epoxomicin) in lung extracts were measured employing the fluorogenic peptide substrate *N*-Suc-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin (chymotryptic-like, CT-L, Biomol), as described (Majetschak *et al.* 2008a; Geng *et al.* 2009; Baker *et al.* 2010). Reaction mixtures contained 1 mmol/L DTE, 2 mmol/L ATP, 5 mmol/L MgCl₂, 10 mmol/L Tris/HCl, pH 8.0, 200 μmol/L peptide

substrate (0 - 400 μ mol/L peptide substrate for the measurement of the substrate dependency) and 0.5 mg/mL tissue extract. All enzyme assays were performed immediately after preparation of the lung extracts to prevent from proteasome inactivation by freeze-thawing.

<u>Western blots</u>: Western blotting with anti-proteasome core (anti- α 5,7, β 1,5,5i,7), β subunit specific antibodies (β 1-7, β 1i, β 2i, β 5i) and densitometric quantification of the chemiluminescence signals was performed as described (Majetschak *et al.* 2008a; Geng *et al.* 2009). All antibodies were obtained from Enzo. Chemiluminescence signals were detected with a Chemidoc imaging system and analyzed using the Quantity One gel analyses software (BioRad). Human erythrocyte 20S proteasome (Boston Biochem) was used as a standard.

<u>Analytical gel filtration</u>: Analytical gel filtration was performed on a Superose 6 - column (GE Healthcare) in 25mmol/L Tris/HCl, pH 7.5, 150 mmol/L NaCl, 2 mmol/L ATP, 5 mmol/L Mg²⁺ at 5°C using the DuoFLow-chromatography system (Bio-Rad). The flow rate was 0.25 ml/min and fractions of 0.5 ml were collected. The column was calibrated using proteins of known molecular mass (thyroglobulin (670kDa), bovine γ -globulin (158kDa), chicken ovalbumin (44kDa), equine myoglobin (17kDa) (all from Bio-Rad).

<u>Statistics.</u> Data are described as mean \pm SD. One-way analysis of variance with Dunnett's multiple comparison test to control for multiple testing were used to compare

differences between groups. Statistical analyses and non-linear regression analyses were calculated with the GraphPad-Prism program (GraphPad-Software). A two-tailed p<0.05 was considered significant.

Results:

Proteasome content

The content of total 20S proteasomes in donor lung extracts was $4.1\pm0.9 \,\mu\text{g/mg}$. As compared with the total 20S content, the amount of 26S proteasome complexes in donor lung extracts was 4-fold lower (0.96±0.23 µg/mg). The molar ratio between free 20S core particles and 26S complexes was 10±3. As compared with donor lungs (molar 20S content: 5.4±1.3 pmol/mg), the content of free 20S proteasomes per mg of protein was similar in extracts from patients with COPD (6.2±1.3 pmol/mg) and significantly increased in lung extracts from patients with IPF (11.1±2.2 pmol/mg) and sarcoidosis (9.8±3.4 pmol/mg; Fig. 1A). Whereas quantification of the 26S content showed a similar tendency, these differences did not reach statistical significance (Fig. 1B). The molar ratios between 20S and 26S proteasomes in lung extracts were similar in all groups (molar 20S/26S ratio: donor lungs - 10.0±3.1; IPF - 9.3±2.9; sarcoidosis - 11.8±6.0; COPD - 7.7±3.9; p>0.05; Fig. 1C). To confirm the relative distribution of 20S and 26S proteasomes, we then performed gel filtration experiments with donor lung extracts (Fig. 1D). Consistent with the molar 20S/26S ratio that we determined by ELISA, 90% of 20S proteasomes in donor lung extracts eluted in fractions that corresponded to a molecular mass of 700 kDa (fractions #27-33), whereas only 10% of 20S proteasomes were detectable at elution positions corresponding to a molecular mass of >1 MDa (fractions #23-26).

Proteasome peptidase activity

Next, we determined the time progression and substrate dependency of the proteasome peptidase activity in the lung extracts. We observed linear enzyme kinetics over 40 min in extracts from donor and diseased lungs (Fig. 2A). The substrate dependency of the proteasome peptidase activity for the chymotrypsin-like peptide substrate showed Michaelis-Menten kinetics. The Michaelis constant (*K*m) was similar in all extracts (*K*m for Suc-LLVY: donor lungs - 126±17 μ M, IPF - 134±30 μ M, Sarc - 247±138 μ M, COPD - 218±148 μ M; r²: 0.83-0.99; p>0.05; Fig. 2B).

As expected based on the quantification of the proteasome content in the lung extracts, chymotrypsin-like proteasome peptidase activity was significantly increased in lung extracts from IPF patients when the enzyme activity was expressed per mg of total extract protein (Fig. 2C). There were no differences among the lung extracts, however, when the specific proteasome peptidase activity was expressed per mol of 20S proteasome, which contains the catalytically active sites (Fig. 2D).

To further characterize the enzymatic properties of the lung proteasome, we tested the sensitivity of the proteasome peptidase activity in lung extracts to the specific proteasome inhibitor epoxomicin (Meng *et al.* 1999). We detected similar inhibition kinetics in extracts from donor lungs and diseased lungs (LogIC₅₀: 6.3 - 6.6, p>0.05; Fig. 2E).

Proteasome subunit composition

To assess the subunit composition of donor and diseased lungs, we first analyzed lung extracts by Western blotting utilizing an antibody against multiple α and β 20S subunits (Fig. 3). Purified human erythrocyte 20S proteasome was used for

comparison because it does not contain inducible immuno-subunits (Claverol et al. 2002; Chen et al. 2009). In contrast to erythrocyte proteasomes in which two bands were detectable, this antibody recognized four major bands in all lung extracts (Fig. 3A/B), suggesting differences in the subunit composition between erythrocyte and lung 20S proteasomes. We then analyzed the expression of constitutive and inducible 20S proteasome β subunits by Western blotting with subunit specific antibodies (Fig. 4). Donor lung extracts contained all constitutive (β 1-7) and immuno (β 1i, β 2i, β 5i) subunits (Fig. 4A-D). All immuno-subunits and their constitutive counterparts were also detectable in extracts from diseased lungs, whereas immuno-subunits were not detectable in human erythrocyte 20S proteasomes (Fig. 4A-E). When membranes with lung extracts that showed obvious differences in the band intensities for the subunits β 1, β 2 or β 5 were re-probed for the corresponding inducible immuno-subunits, we observed an inverse relationship of the band intensities, and vice versa (Fig. 4E). As shown in Fig. 4E for lung extracts from patients with COPD, the chemiluminescence signals for the bands corresponding to the immuno-subunits and their corresponding counterparts in donor lung extracts and extracts from diseased lungs varied considerably and did not provide evidence for a disease associated pattern by Western blotting.

Discussion

In the present pilot study, we detected that proteasome content in lung extracts from patients with IPF and pulmonary sarcoidosis was increased, as compared to that in lung extracts from organ donors and patients with COPD. The relative distribution between 20S and 26S proteasomes was similar and proteasome peptidase activities

were indistinguishable in donor and diseased lungs. All lung extracts contained a mixed composition of inducible 20S β immuno-subunits and their constitutive counterparts. Disease associated alterations in 20S proteasome subunit distribution, however, could not be identified.

The amount of 20S proteasomes that we determined in donor lungs is in agreement with the cellular 20S content that has been estimated based on Western blot analyses in human embryonic pulmonary epithelial cells (L132; $6.9\pm2.8 \mu g/mg$) (Brooks *et al.* 2000). A several fold excess of 20S over 26S proteasomes has been reported in rat liver and L132 cells previously (Brooks *et al.* 2000). Along with our finding that the molar 20S/26S proteasome ratio is approximately 10 in human lung extracts, these data suggest that the free 20S is predominant in solid organs. Our findings suggest that IPF and, to a lesser extent, sarcoidosis are associated with increased expression of lung proteasomes in which the physiological equilibrium between 20S and 26S proteasomes is maintained. It should be noted, however, that quantification of proteasome content per mg of protein likely underestimates proteasome content in lungs from patients with IPF and sarcoidosis, because in both diseases the fibrotic remodeling will lead to an increased protein content of the homogenates.

Whereas the human lung proteasome in patients with IPF and sarcoidosis has not been studied previously, reduced lung proteasome peptidase activity per mg of protein has been described in patients with COPD (Malhotra *et al.* 2009). In this study, however, proteasome peptidase activity was tested after sodium dodecyl sulfate (SDS) activation of a proteasome fraction that was enriched using a ubiquitin-like (UbL) domain linked to affinity matrix beads (Malhotra *et al.* 2009). Although this observation

may suggest changes in substrate recognition by the proteasome (Tanaka *et al.* 1989; Dahlmann *et al.* 1993), information on the enzymatic activity of proteasomes without SDS activation has not been provided (Malhotra *et al.* 2009). Thus, these findings are not contradictory with our enzyme activity measurements in minimally manipulated lung extracts.

Human liver, colon, small intestine and kidney have been shown to contain 20S proteasomes with a mixed composition of standard and inducible immuno-subunits (Baldovino *et al.* 2006; Visekruna *et al.* 2009; Guillaume *et al.* 2010). Furthermore, changes in the subunit composition of 20S proteasomes under pathological conditions have been described in animal models and in patients (Barton *et al.* 2002; Visekruna *et al.* 2009; Zheng *et al.* 2012). Our findings demonstrate for the first time that all immuno-subunits and their constitutive counterparts are also detectable in extracts from donor and diseased lungs. Our Western blot experiments further suggest that both inducible immuno-subunits and their constitutive counterparts form the 20S core particle in lung extracts, which is in agreement with recent observations in lung tumor cell lines (Guillaume *et al.* 2010). Furthermore, the observation that multiple antibodies reacted with more than one band is consistent with the existence of multiple isoforms of most of the 20S proteasome subunits (Claverol *et al.* 2002; Chen *et al.* 2009).

The heterogeneity of the subunit distribution and the large variability among individual specimens that we detected could be explained by the exposure to inhaled particles and microbes throughout a person's lifetime (Nelson *et al.* 2000; Kwak *et al.* 2007; Kremer *et al.* 2010), which is specific to the individual and may have masked disease associated alterations.

Whereas we were unable to differentiate a disease specific pattern of the lung 20S proteasome subunit composition, we cannot exclude that quantification of the subunit composition with more accurate and precise methods, such as subunit specific ELISAs, may be able to detect statistically significant differences between proteasomes from donor and diseased lungs. Our finding that the specific proteasome peptidase activity was similar in all extracts, however, argues against this possibility, because such differences would be expected to alter the specific enzyme activity (Eleuteri *et al.* 1997; Guillaume *et al.* 2010; Zu *et al.* 2010; Rodriguez *et al.* 2012; Zheng *et al.* 2012).

Limitations of this pilot study are the small sample size and the limited information about the donor and patient history. Therefore, we can currently not comment on the possible effects of other biological or behavioral factors, such as cigarette smoking or alpha1-antitrypsin mutations (Novoradovskaya *et al.* 1998; van Rijt *et al.* 2012). Furthermore, we have utilized crude lung extracts for enzyme activity measurements; thus, proteasomes from non-lung cells, such as erythrocytes, and extracellular proteasomes may have confounded our findings. As erythrocyte proteasomes, however, do not contain 20S immuno-subunits and the concentrations of extracellular proteasomes are far below intracellular concentrations, such confounding effects appear negligible (Claverol et al. 2002; Chen et al. 2009; Majetschak *et al.* 2008b, Albright *et al.* 2009).

Several lines of evidence suggest that the proteasome is involved in the pathophysiology of organ fibrosis and proteasome inhibition has been shown to inhibit TGF-β1 induced gene expression in primary human lung fibroblasts from healthy individuals and patients with IPF (Fineschi *et al.* 2006; Mutlu *et al.* 2012). Moreover,

increases in proteasome peptidase activities have been detected in lung extracts several days after injury, which is known to lead to repair with fibrosis, and proteasome inhibition has been described to reduce lung fibrosis in some animal models (Matute-Bello *et al.* 2008; Manning *et al.* 2009; Mutlu *et al.* 2012). As IPF and end-stage pulmonary sarcoidosis are characterized by a fibrotic remodeling of the lung, our findings support the concept that the higher content of lung proteasomes contributes to the pathophysiology of human fibrotic lung diseases. Further exploration of the proteasome as a drug target for these currently incurable diseases appears justified.

Acknowledgement

This study was supported in part by NIHT32 GM008750 (to RLG) and the Dr. Ralph and Marian Falk Medical Research Trust. The authors thank Jacqueline Romero for technical help.

References

ALBRIGHT JM, ROMERO J, SAINI V, SIXT SU, BIRD MD, KOVACS EJ, GAMELLI RL, PETERS J, MAJETSCHAK M: Proteasomes in human bronchoalveolar lavage fluid after burn and inhalation injury. *J Burn Care Res* **30**: 948-956, 2009. BAKER TA, GENG Q, ROMERO J, PICKEN MM, GAMELLI RL, MAJETSCHAK M: Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation. *Bioch Biophys Res Commun* **401**: 548-553, 2010.

BALDOVINO S, PICCININI M, ANSELMINO A, RAMONDETTI C, RINAUDO MT,

COSTANZO P, SENA LM, ROCCATELLO D: Structural and functional properties of proteasomes purified from the human kidney. *J Nephrol* **19**: 710-716, 2006.

BARTON LF, CRUZ M, RANGWALA R, DEEPE GS, JR., MONACO JJ: Regulation of immunoproteasome subunit expression in vivo following pathogenic fungal infection. *J Immunol* **169**: 3046-3052, 2002.

BAUMEISTER W, WALZ J, ZUHL F, SEEMULLER E: The proteasome: paradigm of a self-compartmentalizing protease. *Cell* **92**: 367-380, 1998.

BODAS M, TRAN I, VIJ N: Therapeutic strategies to correct proteostasis-imbalance in chronic obstructive lung diseases. *Curr Mol Med* **12**: 807-814, 2012.

BROOKS P, FUERTES G, MURRAY RZ, BOSE S, KNECHT E, RECHSTEINER MC, HENDIL KB, TANAKA K, DYSON J, RIVETT J: Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. *Biochem J* **346 Pt 1**: 155-161, 2000.

BUNN PA, JR.: The potential role of proteasome inhibitors in the treatment of lung cancer. *Clin Cancer Res* **10**: 4263s-4265s, 2004.

CHEN G, LUO Y, WANG X, ZHAO Z, LIU H, ZHANG H, LI Z: A relatively simple and economical protocol for proteomic analyses of human 20S proteasome: Compatible with both scaled-up and scaled-down purifications. *Electrophoresis* **30**: 2422-2430, 2009.

CLAVEROL S, BURLET-SCHILTZ O, GIRBAL-NEUHAUSER E, GAIRIN JE,

MONSARRAT B: Mapping and structural dissection of human 20 S proteasome using proteomic approaches. *Mol Cell Proteomics* **1**: 567-578, 2002.

DAHLMANN B, BECHER B, SOBEK A, EHLERS C, KOPP F, KUEHN L: In vitro activation of the 20S proteasome. *Enzyme Protein* **47**: 274-284, 1993.

ELEUTERI AM, KOHANSKI RA, CARDOZO C, ORLOWSKI M: Bovine spleen multicatalytic proteinase complex (proteasome). Replacement of X, Y, and Z subunits by LMP7, LMP2, and MECL1 and changes in properties and specificity. *J Biol Chem* **272**: 11824-11831, 1997.

EYTAN E, ARMON T, HELLER H, BECK S, HERSHKO A: Ubiquitin C-terminal hydrolase activity associated with the 26 S protease complex. *J Biol Chem* **268**: 4668-4674, 1993.

FINESCHI S, REITH W, GUERNE PA, DAYER JM, CHIZZOLINI C: Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. *FASEB J* **20**: 562-564, 2006.

GALLASTEGUI N, GROLL M: The 26S proteasome: assembly and function of a destructive machine. *Trends Biochem Sci* **35**: 634-642, 2010.

GENG Q, ROMERO J, SAINI V, BAKER TA, PICKEN MM, GAMELLI RL,

MAJETSCHAK M: A subset of 26S proteasomes is activated at critically low ATP concentrations and contributes to myocardial injury during cold ischemia. *Biochem Biophys Res Commun* **390**: 1136-1141, 2009.

GOMES AV, ZONG C, EDMONDSON RD, LI X, STEFANI E, ZHANG J, JONES RC, THYPARAMBIL S, WANG GW, QIAO X, BARDAG-GORCE F, PING P: Mapping the murine cardiac 26S proteasome complexes. *Circ Res* **99**: 362-371, 2006. GROLL M, HUBER R: Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. *Biochim Biophys Acta* **1695**: 33-44, 2004.

GUILLAUME B, CHAPIRO J, STROOBANT V, COLAU D, VAN HOLLE B, PARVIZI G, BOUSQUET-DUBOUCH MP, THEATE I, PARMENTIER N, VAN DEN EYNDE BJ: Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. *Proc Natl Acad Sci U S A* **107**: 18599-18604, 2010.

HERSHKO A, CIECHANOVER A: The ubiquitin system. *Annu Rev Biochem* **67**: 425-479, 1998.

KREMER M, HENN A, KOLB C, BASLER M, MOEBIUS J, GUILLAUME B, LEIST M, VAN DEN EYNDE BJ, GROETTRUP M: Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice. *J Immunol* **185**: 5549-5560, 2010.

KWAK MK, HUANG B, CHANG H, KIM JA, KENSLER TW: Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: enhanced activity for degradation of abnormal protein. *Life Sci* **80**: 2411-2420, 2007.

LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ: Protein measurement with the Folin phenol reagent. *J Biol Chem* **193**: 265-275, 1951.

MAJETSCHAK M, PATEL MB, SORELL LT, LIOTTA C, LI S, PHAM SM: Cardiac proteasome dysfunction during cold ischemic storage and reperfusion in a murine heart transplantation model. *Biochem Biophys Res Commun* **365**: 882-888, 2008a.

MAJETSCHAK M, PEREZ M, SORELL LT, LAM J, MALDONADO ME, HOFFMAN RW: Circulating 20S proteasome levels in patients with mixed connective tissue disease and systemic lupus erythematosus. *Clin Vaccine Immunol* **15**:1489-1493, 2008b.

MAJETSCHAK M, SORELL LT: Immunological methods to quantify and characterize proteasome complexes: development and application. *J Immunol Methods* **334**: 91-103, 2008.

MALHOTRA D, THIMMULAPPA R, VIJ N, NAVAS-ACIEN A, SUSSAN T, MERALI S, ZHANG L, KELSEN SG, MYERS A, WISE R, TUDER R, BISWAL S: Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. *Am J Respir Crit Care Med* **180**: 1196-1207, 2009.

MANNING EW, 3RD, PATEL MB, GARCIA-COVARRUBIAS L, RAHNEMAI-AZAR AA, PHAM SM, MAJETSCHAK M: Proteasome peptidase activities parallel histomorphological and functional consequences of ischemia-reperfusion injury in the lung. *Exp Lung Res* **35**: 284-295, 2009.

MATUTE-BELLO G, FREVERT CW, MARTIN TR: Animal models of acute lung injury. *Am J Physiol Lung Cell Mol Physiol* **295**: L379-399, 2008.

MENG L, MOHAN R, KWOK BH, ELOFSSON M, SIN N, CREWS CM: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. *Proc Natl Acad Sci U S A* **96**: 10403-10408, 1999.

MUTLU GM, BUDINGER GR, WU M, LAM AP, ZIRK A, RIVERA S, URICH D,

CHIARELLA SE, GO LH, GHOSH AK, SELMAN M, PARDO A, VARGA J, KAMP DW,

CHANDEL NS, SZNAJDER JI, JAIN M: Proteasomal inhibition after injury prevents fibrosis by modulating TGF-beta(1) signalling. *Thorax* **67**: 139-146, 2012.

NELSON JE, LOUKISSA A, ALTSCHULLER-FELBERG C, MONACO JJ, FALLON JT, CARDOZO C: Up-regulation of the proteasome subunit LMP7 in tissues of endotoxemic

rats. *J Lab Clin Med* **135**: 324-331, 2000.

NOVORADOVSKAYA N, LEE J, YU ZX, FERRANS VJ, BRANTLY M: Inhibition of intracellular degradation increases secretion of a mutant form of alpha1-antitrypsin associated with profound deficiency. *J Clin Invest* **101**:2693-26701, 1998.

ORLOWSKI M: The multicatalytic proteinase complex, a major extralysosomal proteolytic system. *Biochemistry* **29**: 10289-10297, 1990.

ORLOWSKI M, WILK S: Ubiquitin-independent proteolytic functions of the proteasome. *Arch Biochem Biophys* **415**: 1-5, 2003.

ROCK KL, GOLDBERG AL: Degradation of cell proteins and the generation of MHC class I-presented peptides. *Annu Rev Immunol* **17**: 739-779, 1999.

RODRIGUEZ KA, EDREY YH, OSMULSKI P, GACZYNSKA M, BUFFENSTEIN R:

Altered composition of liver proteasome assemblies contributes to enhanced

proteasome activity in the exceptionally long-lived naked mole-rat. PLoS One 7:

e35890, 2012.

SIJTS EJ, KLOETZEL PM: The role of the proteasome in the generation of MHC class I ligands and immune responses. *Cell Mol Life Sci* **68**: 1491-1502, 2011.

TANAKA K, YOSHIMURA T, ICHIHARA A: Role of substrate in reversible activation of proteasomes (multi-protease complexes) by sodium dodecyl sulfate. *J Biochem* **106**: 495-500, 1989.

VAN RIJT SH, KELLER IE, JOHN G, KOHSE K, YILDIRIM AÖ, EICKELBERG O,

MEINERS S: Acute cigarette smoke exposure impairs proteasome function in the lung.

Am J Physiol Lung Cell Mol Physiol **303**: L814-823, 2012.

VISEKRUNA A, JOERIS T, SCHMIDT N, LAWRENZ M, RITZ JP, BUHR HJ,

STEINHOFF U: Comparative expression analysis and characterization of 20S

proteasomes in human intestinal tissues: The proteasome pattern as diagnostic tool for

IBD patients. Inflamm Bowel Dis 15: 526-533, 2009.

WEISS CH, BUDINGER GR, MUTLU GM, JAIN M: Proteasomal regulation of pulmonary fibrosis. *Proc Am Thorac Soc* **7**: 77-83, 2010.

ZHAO J, WEI J, MIALKI RK, MALLAMPALLI DF, CHEN BB, COON T, ZOU C,

MALLAMPALLI RK, ZHAO Y: F-box protein FBXL19-mediated ubiquitination and

degradation of the receptor for IL-33 limits pulmonary inflammation. Nat Immunol 13:

651-658, 2012.

ZHENG J, DASGUPTA A, BIZZOZERO OA: Changes in 20S subunit composition are largely responsible for altered proteasomal activities in experimental autoimmune encephalomyelitis. *J Neurochem* **121**: 486-494, 2012.

ZU L, BEDJA D, FOX-TALBOT K, GABRIELSON KL, VAN KAER L, BECKER LC, CAI ZP: Evidence for a role of immunoproteasomes in regulating cardiac muscle mass in diabetic mice. *J Mol Cell Cardiol* **49**: 5-15, 2010.

Figure Legends:

Figure 1: Proteasome content in human lung extracts. DL: donor lung. IPF: idiopathic pulmonary fibrosis. COPD: chronic obstructive lung disease. Sarc: sarcoidosis. RFU: relative fluorescence units. Boxes extend from the 25th to 75th percentile, the horizontal line and error bars show the median, minimum and maximum. *: p<0.05 vs. DL. **A.** 20S/mg; n=5-7/group. **B.** 26S/mg, n=5-7/group. **C.** molar 20S/26S ratio, n=5-7/group. **D.** A donor lung extract (0.5 ml) was separated on a Superose 6 column. The 20S concentrations in the eluted fractions were quantified by enzyme linked immunosorent assay. The arrows show the elution positions of proteins with known molecular masses.

Figure 2: **Proteasome peptidase activities in human lung extracts.** DL: donor lung. IPF: idiopathic pulmonary fibrosis. COPD: chronic obstructive pulmonary disease. Sarc: sarcoidosis. RFU: relative fluorescence units. Boxes extend from the 25th to 75th percentile, the horizontal line and error bars show the median, minimum and maximum. *: p<0.05 vs. DL. **A.** Time progression of the chymotrypsin-like proteasome peptidase activity (CT-L). **B.** Substrate dependency of the CT-L. **C.** CT-L/mg, n=5-7/group. **D.** CT-L/mol 20S, n=5-7/group. **E.** Epoxomicin sensitivity of the CT-L in % (100% = no epoxomicin; 0% = 7μM epoxomicin), n=3/group, mean±SD.

Figure 3: 20S proteasome core subunits (α 5,7, β 1,5,5i,7) in human lung extracts. Western blots with anti-proteasome core (α 5,7, β 1,5,5i,7). Each lane contains 300 pmol of 20S proteasomes. The migration positions of molecular mass standards are

indicated. **A.** E: human erythrocyte 20S proteasome. DL: donor lung. IPF: idiopathic pulmonary fibrosis. **B.** DL: donor lung. COPD: chronic obstructive pulmonary disease. IPF: idiopathic pulmonary fibrosis. Sarc: sarcoidosis.

Figure 4: Constitutive and inducible 20S proteasome β subunits in human lung extracts. E: human erythrocyte 20S proteasome. DL: donor lung. IPF: idiopathic pulmonary fibrosis. COPD: chronic obstructive pulmonary disease. Sarc: sarcoidosis. Each lane contains 300 pmol of 20S proteasomes. **A.** Western blots with anti-β1 and anti-β1i. **B.** Western blots with anti-β2 and anti-β2i. **C.** Western blots with anti-β5 and anti-β5i. **D.** Western blots with anti-β3,4,6,7. **E.** Top: Western blots with anti-β1, anti-β2i and anti-β5. Bottom: Membranes were stripped and re-probed with antibodies against the corresponding inducible or constitutive counterparts, as indicated. Lanes 1 and 2 contain lung extracts from two different patients with COPD.






Figure 2

